Market Overview

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ltd. On FDA Panel Outcome

Share:

In a report published Friday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00.

In the report, Sterne Agee noted, “The outcome of today's FDA Panel on mu opioid antagonists, although not conclusive, suggests that Salix likely has a path to approval for Relistor for the treatment of opioid-induced constipation in non-cancer pain patients. This could potentially add an incremental $500mn-$750mn in product sales. Per our calculations, each $100mn in Relistor sales equates to $2-$3 in fair value for SLXP. We expect further insight into the future of Relistor tomorrow, as Salix's partner on the drug, Progenics Pharmaceuticals (PGNX, $4.22, Not Rated) is hosting a call on this topic.”

Salix Pharmaceuticals Ltd. closed on Thursday at $113.80.

Latest Ratings for SLXP

DateFirmActionFromTo
Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (SLXP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
FNKODA DavidsonMaintains9.5
FCAUCFRAReiterates16.0
PODDCFRAMaintains162.0
MRNANeedhamMaintains35.0
REALB of A SecuritiesMaintains21.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com